Developer docs
API playgroundTry for free, no card

Search company profiles

PolyBio

Full company profile

uuid003c356

Namestring
PolyBio
Legal namestring
PolyBio Research Foundation
Websiteurl
polybio.org
Company typeenum
Private
Founded yearint
2021
Descriptiontext

PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation founded in 2021 and headquartered in Medford, Massachusetts. It advances research into how viral, bacterial, and parasite infections contribute to chronic disease and aging, with primary focus on Long COVID, Chronic Lyme Disease, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and other post-infectious conditions. The foundation operates a consortium-style model, coordinating 54+ active research projects and 6 clinical trials across leading U.S. academic and research institutions including Harvard, Stanford, Yale, Mount Sinai, UCSF, the University of Pennsylvania, the J. Craig Venter Institute, and Arizona State University. PolyBio-affiliated work has produced publications in high-impact journals such as Nature and Cell.

The foundation's core technical surface spans diagnostic development (including the VIPER program with $1.35M deployed to UCSF and the MENSA program), tissue and biomarker analysis, neuroimaging, microbiome research, and clinical trials such as a Balvi Fund-supported rapamycin study and HIV antiviral investigations. Its underlying platform is best characterized as a coordinated research network rather than a single technology stack; the foundation provides funding, shared protocols, and translational coordination, and is now extending into commercialization via a newly launched Commercialization Advisory Network. Underlying assets include multi-institutional tissue repositories and biomarker datasets that are difficult to replicate outside this consortium structure.

As a nonprofit, PolyBio does not generate commercial revenue through product sales; its income is donation- and grant-based. Since inception, the foundation has disbursed more than $50 million in research funding, with anchor donors including the Balvi Fund (associated with Vitalik Buterin) and the Steve & Alexandra Cohen Foundation. Its customers, in a functional sense, are patient communities affected by infection-associated chronic diseases, while its counterparties are academic research partners, clinical trial sponsors, and major philanthropic funders. The Commercialization Advisory Network represents a deliberate shift toward capturing downstream value from research outputs rather than remaining a pure grant-making entity.

Short descriptiontext

PolyBio Research Foundation is a 501(c)(3) nonprofit founded in 2021 that funds and coordinates research on infection-driven chronic diseases, including Long COVID, ME/CFS, and chronic Lyme, across leading U.S. academic institutions and has disbursed over $50M since inception.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMedford, United States
HQ citystring
Medford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infection-associated chronic disease research, Long COVID research, pathogen persistence studies, clinical trial coordination, nonprofit biomedical research
Industry4 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Nonprofit Biomedical Research
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Philanthropic Donations
TypeGrants Donations
Description

PolyBio is a 501(c)(3) nonprofit organization that receives funding through donations from individuals, foundations, and partners. The website prominently features a 'Donate' button and mentions donor partnerships as key to empowering their mission to fight on behalf of millions of ME/CFS and chronic illness patients.

polybio.org
2Research Grants and Funding
TypeOthers
Description

Funding from organizations such as the Balvi Fund (Vitalik Buterin's fund) to expand clinical trials like the Long COVID rapamycin trial, and initial $1.35 million deployed to UCSF for VIPER program.

nature.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation that coordinates collaborative research on how viral, bacterial, and parasite infections drive chronic disease and aging. It funds and manages the Long COVID Cure Initiative, the VIPER diagnostic validation program, the Long COVID Research Consortium, multiple clinical trials (including low-dose rapamycin and repurposed HIV antivirals), and the MENSA diagnostic testing platform for Long COVID, ME/CFS, and Chronic Lyme Disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • $50M+ in research fund disbursement
+4 more records
Product overview1 text field

PolyBio Research Foundation is a 501(c)(3) research organization advancing research on how viral, bacterial, and parasite infections drive chronic disease and aging. The organization's primary offerings include the Long COVID Cure Initiative (LCCI), a four-step translational research program; VIPER, the diagnostic validation program within LCCI; the Long COVID Research Consortium connecting scientists from major institutions; and the Commercialization Advisory Network. PolyBio also conducts multiple clinical trials including low-dose rapamycin and repurposed HIV antivirals, and supports the MENSA diagnostic testing platform for viral immune response detection.

Product and service7 records
1Long COVID Cure Initiative (LCCI)
CategoryTranslational research program
Description

A four-step translational research program designed to move biological discovery into real-world treatments for Long COVID, including precise diagnosis, personalized care linking patient biology to therapies, and acceleration of cures through science-industry-philanthropy collaboration. Directed at scientists, clinicians, and patients affected by Long COVID.

2VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort)
CategoryDiagnostic validation program
Description

First phase of the Long COVID Cure Initiative: a large-scale diagnostic validation program that conducts head-to-head evaluation of leading diagnostic approaches to determine which tests most accurately detect core disease mechanisms of Long COVID. Designed for researchers, clinicians, and diagnostic developers working on Long COVID.

3Long COVID Research Consortium
CategoryResearch consortium
Description

Scientific collaboration involving scientists and clinicians from Harvard Medical School, Stanford University, University of Pennsylvania, Icahn School of Medicine at Mount Sinai, Yale University, UCSF, and J. Craig Venter Institute, designed to rapidly and comprehensively study Long COVID. For researchers studying infection-associated chronic diseases.

4Commercialization Advisory Network
CategoryTranslation and commercialization network
Description

Initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments through industry partnerships and commercialization expertise. For diagnostics developers, therapeutics companies, and commercialization partners.

5Long COVID Low-Dose Rapamycin Clinical Trial
CategoryClinical trial
Description

Double-blinded randomized controlled pilot clinical trial at Mount Sinai's Cohen Center for Recovery from Complex Chronic Illness to determine if low-dose rapamycin can improve symptoms in patients with Long COVID. For Long COVID patients and clinical investigators.

6Repurposed HIV Antivirals Clinical Trial (Truvada & Maraviroc)
CategoryClinical trial
Description

Clinical trial testing if two repurposed HIV antivirals (Truvada and Maraviroc) can reduce symptom burden in patients with Long COVID over 90 days, with analyses of infectious, immune, and metabolic biomarkers. For Long COVID patients and clinical investigators.

7MENSA Virus Immune Snapshot Testing
CategoryDiagnostic test
Description

A diagnostic method that captures virus-specific immune cell responses secreted exclusively from circulating human plasmablasts, providing an immune snapshot to clarify if a patient's immune system is responding to persistent viral infection. For clinicians and researchers studying chronic viral infections.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Initial $1.35 million deployed to UCSF to initiate the VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort) program, the first large-scale diagnostic validation program for Long COVID.

2Harvard Medical School
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Harvard Medical School is part of the Long COVID Research Consortium, contributing scientists and clinicians to collaborative research projects studying infection-associated chronic diseases.

polybio.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Stanford University is part of the Long COVID Research Consortium, contributing researchers to collaborative studies on Long COVID and related conditions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Yale University is part of the Long COVID Research Consortium. Dr. Akiko Iwasaki's lab at Yale is studying SARS-CoV-2 and Long COVID biological mechanisms, and is involved in the rapamycin clinical trial.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mount Sinai is part of the Long COVID Research Consortium. The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai is a key clinical trial site. Dr. David Putrino serves as Director of Rehabilitation Innovation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UCSF is part of the Long COVID Research Consortium and received initial $1.35 million funding for the VIPER diagnostic validation program. Dr. Tim Henrich leads research on viral persistence and ImmunoPET-CT imaging.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University of Pennsylvania is part of the Long COVID Research Consortium. Dr. John Wherry's lab studies T cell responses and exhaustion in Long COVID.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

J. Craig Venter Institute is part of the Long COVID Research Consortium. Dr. Marcelo Freire's lab at JCVI studies oral pathogens and chronic disease.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mount Sinai's Center for Post-COVID Care, launched in May 2020 as the first major multidisciplinary Long COVID treatment and research center in the USA, collaborates on clinical trials and research projects.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Dr. Kevin Tracey, president and CEO of Feinstein Institutes, is interviewed by PolyBio and is an expert on vagus nerve signaling and bioelectronic medicine relevant to Long COVID research.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Dr. Monica Embers' lab at Tulane studies Borrelia burgdorferi (Lyme disease) and is interviewed by PolyBio for Lyme and tissue research collaboration.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Dr. Kim Lewis, University Distinguished Professor at Northeastern and Director of the Antimicrobial Discovery Center, collaborates on Lyme disease persister cell research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Benjamin Readhead's team at ASU is validating a cytomegalovirus-based biomarker for Alzheimer's disease and studying infectious contributions to neurodegenerative diseases.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Dr. Liisa Selin's lab studies T cell exhaustion and viral activity in ME/CFS, collaborating on understanding immune responses in chronic illness.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Dr. Sara Cherry's lab uses tissue models and screening technologies to identify antiviral strategies for SARS-CoV-2 persistence research.

16Commercialization Advisory Network
Strategic tierCoreTypeOthers
Description

A new initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments.

polybio.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Patient-led research collaborative focused on Long COVID and chronic illness, producing peer-reviewed publications. Highly comparable grassroots, patient-centered research model targeting similar conditions.

TypeDirect peer
Description

Genomics and infectious disease research organization that is both a PolyBio consortium partner and a peer in microbiome/metagenomic chronic disease research. Direct overlap on pathogen-driven disease research.

3Howard Hughes Medical Institute
TypeBroad incumbent
Description

Large biomedical research organization funding investigator-driven science across universities. Comparable model of distributing research funding to top-tier academic labs to drive discovery.

TypeBroad incumbent
Description

Major biomedical research institute conducting translational research on chronic and infectious diseases. Overlapping scientific scope on pathogen persistence and microbiome-driven disease.

TypeDirect peer
Description

501(c)(3) nonprofit research foundation focused on ME/CFS, Long COVID, and related infection-associated chronic diseases. Highly comparable mission, funding model, and disease focus as PolyBio.

TypeDirect peer
Description

Long-standing nonprofit organization dedicated to ME/CFS and Long COVID research, advocacy, and patient support. Overlapping disease focus, philanthropic funding model, and research consortium structure.

TypeEmerging player
Description

Research institute focused on CRISPR and genomic approaches to infectious disease and chronic illness. Comparable emerging research organization with overlap in pathogen-driven disease focus.

TypeBroad incumbent
Description

Federal research initiative with >$1B funding dedicated to studying Long COVID. Operates in the same disease area with vastly greater resources; both share the goal of understanding post-viral chronic illness.

TypeBroad incumbent
Description

Major philanthropic initiative funding biomedical research, including infectious disease and inflammation. Overlapping mission in advancing disease research via academic partnerships and large-scale funding.

10Cohen Center for Recovery from Complex Chronic Illness (Mount Sinai)
TypeDirect peer
Description

Clinical and research center at Mount Sinai focused on Long COVID and complex chronic illness; receives PolyBio funding and conducts clinical trials in the same disease space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PolyBio

Nonprofit Biomedical Researchpolybio.org

PolyBio Research Foundation is a 501(c)(3) nonprofit founded in 2021 that funds and coordinates research on infection-driven chronic diseases, including Long COVID, ME/CFS, and chronic Lyme, across leading U.S. academic institutions and has disbursed over $50M since inception.

What PolyBio does

PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation founded in 2021 and headquartered in Medford, Massachusetts. It advances research into how viral, bacterial, and parasite infections contribute to chronic disease and aging, with primary focus on Long COVID, Chronic Lyme Disease, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and other post-infectious conditions. The foundation operates a consortium-style model, coordinating 54+ active research projects and 6 clinical trials across leading U.S. academic and research institutions including Harvard, Stanford, Yale, Mount Sinai, UCSF, the University of Pennsylvania, the J. Craig Venter Institute, and Arizona State University. PolyBio-affiliated work has produced publications in high-impact journals such as Nature and Cell.

The foundation's core technical surface spans diagnostic development (including the VIPER program with $1.35M deployed to UCSF and the MENSA program), tissue and biomarker analysis, neuroimaging, microbiome research, and clinical trials such as a Balvi Fund-supported rapamycin study and HIV antiviral investigations. Its underlying platform is best characterized as a coordinated research network rather than a single technology stack; the foundation provides funding, shared protocols, and translational coordination, and is now extending into commercialization via a newly launched Commercialization Advisory Network. Underlying assets include multi-institutional tissue repositories and biomarker datasets that are difficult to replicate outside this consortium structure.

As a nonprofit, PolyBio does not generate commercial revenue through product sales; its income is donation- and grant-based. Since inception, the foundation has disbursed more than $50 million in research funding, with anchor donors including the Balvi Fund (associated with Vitalik Buterin) and the Steve & Alexandra Cohen Foundation. Its customers, in a functional sense, are patient communities affected by infection-associated chronic diseases, while its counterparties are academic research partners, clinical trial sponsors, and major philanthropic funders. The Commercialization Advisory Network represents a deliberate shift toward capturing downstream value from research outputs rather than remaining a pure grant-making entity.

PolyBio firmographics

Firmographics
Name
PolyBio
Legal name
PolyBio Research Foundation
Website
https://polybio.org
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
PolyBio Research Foundation is a 501(c)(3) nonprofit founded in 2021 that funds and coordinates research on infection-driven chronic diseases, including Long COVID, ME/CFS, and chronic Lyme, across leading U.S. academic institutions and has disbursed over $50M since inception.
Ownership category
akta.pro rank

PolyBio industry classification

Industry
Product category
Nonprofit Biomedical Research
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYEDAHAGAI
Biomedical Sciences & Medical Research Institutes (University-Based)
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

Keywords

  • Infection-associated chronic disease research
  • Long COVID research
  • Pathogen persistence studies
  • Clinical trial coordination
  • Nonprofit biomedical research

Where PolyBio is headquartered

Location

Headquarters

HQ city
Medford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PolyBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Philanthropic Donations: PolyBio is a 501(c)(3) nonprofit organization that receives funding through donations from individuals, foundations, and partners. The website prominently features a 'Donate' button and mentions donor partnerships as key to empowering their mission to fight on behalf of millions of ME/CFS and chronic illness patients.
  2. Research Grants and Funding: Funding from organizations such as the Balvi Fund (Vitalik Buterin's fund) to expand clinical trials like the Long COVID rapamycin trial, and initial $1.35 million deployed to UCSF for VIPER program.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

PolyBio product offering

Product offering

Core offering

PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation that coordinates collaborative research on how viral, bacterial, and parasite infections drive chronic disease and aging. It funds and manages the Long COVID Cure Initiative, the VIPER diagnostic validation program, the Long COVID Research Consortium, multiple clinical trials (including low-dose rapamycin and repurposed HIV antivirals), and the MENSA diagnostic testing platform for Long COVID, ME/CFS, and Chronic Lyme Disease.

Product overview

PolyBio Research Foundation is a 501(c)(3) research organization advancing research on how viral, bacterial, and parasite infections drive chronic disease and aging. The organization's primary offerings include the Long COVID Cure Initiative (LCCI), a four-step translational research program; VIPER, the diagnostic validation program within LCCI; the Long COVID Research Consortium connecting scientists from major institutions; and the Commercialization Advisory Network. PolyBio also conducts multiple clinical trials including low-dose rapamycin and repurposed HIV antivirals, and supports the MENSA diagnostic testing platform for viral immune response detection.

Differentiator

Problem solved

Functional benefit

Products and services

  • Long COVID Cure Initiative (LCCI) A four-step translational research program designed to move biological discovery into real-world treatments for Long COVID, including precise diagnosis, personalized care linking patient biology to therapies, and acceleration of cures through science-industry-philanthropy collaboration. Directed at scientists, clinicians, and patients affected by Long COVID.
  • VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort) First phase of the Long COVID Cure Initiative: a large-scale diagnostic validation program that conducts head-to-head evaluation of leading diagnostic approaches to determine which tests most accurately detect core disease mechanisms of Long COVID. Designed for researchers, clinicians, and diagnostic developers working on Long COVID.
  • Long COVID Research Consortium Scientific collaboration involving scientists and clinicians from Harvard Medical School, Stanford University, University of Pennsylvania, Icahn School of Medicine at Mount Sinai, Yale University, UCSF, and J. Craig Venter Institute, designed to rapidly and comprehensively study Long COVID. For researchers studying infection-associated chronic diseases.
  • Commercialization Advisory Network Initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments through industry partnerships and commercialization expertise. For diagnostics developers, therapeutics companies, and commercialization partners.
  • Long COVID Low-Dose Rapamycin Clinical Trial Double-blinded randomized controlled pilot clinical trial at Mount Sinai's Cohen Center for Recovery from Complex Chronic Illness to determine if low-dose rapamycin can improve symptoms in patients with Long COVID. For Long COVID patients and clinical investigators.
  • Repurposed HIV Antivirals Clinical Trial (Truvada & Maraviroc) Clinical trial testing if two repurposed HIV antivirals (Truvada and Maraviroc) can reduce symptom burden in patients with Long COVID over 90 days, with analyses of infectious, immune, and metabolic biomarkers. For Long COVID patients and clinical investigators.
  • MENSA Virus Immune Snapshot Testing A diagnostic method that captures virus-specific immune cell responses secreted exclusively from circulating human plasmablasts, providing an immune snapshot to clarify if a patient's immune system is responding to persistent viral infection. For clinicians and researchers studying chronic viral infections.

Quantifiable outcome

  • $50M+ in research fund disbursement
  • +4 more outcomes

Companies that use PolyBio

Customer profile

Segments3 records

Ideal customer profiles3 records

PolyBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

PolyBio partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and secondary.

  • University of California San Francisco (UCSF)coreStrategic or Co-development Partner · 24 March 2026Initial $1.35 million deployed to UCSF to initiate the VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort) program, the first large-scale diagnostic validation program for Long COVID.
  • Harvard Medical SchoolcoreStrategic or Co-development PartnerHarvard Medical School is part of the Long COVID Research Consortium, contributing scientists and clinicians to collaborative research projects studying infection-associated chronic diseases.
  • Stanford UniversitycoreStrategic or Co-development PartnerStanford University is part of the Long COVID Research Consortium, contributing researchers to collaborative studies on Long COVID and related conditions.
  • Yale UniversitycoreStrategic or Co-development PartnerYale University is part of the Long COVID Research Consortium. Dr. Akiko Iwasaki's lab at Yale is studying SARS-CoV-2 and Long COVID biological mechanisms, and is involved in the rapamycin clinical trial.
  • Icahn School of Medicine at Mount SinaicoreStrategic or Co-development PartnerMount Sinai is part of the Long COVID Research Consortium. The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai is a key clinical trial site. Dr. David Putrino serves as Director of Rehabilitation Innovation.
  • University of California San Francisco (UCSF)coreStrategic or Co-development PartnerUCSF is part of the Long COVID Research Consortium and received initial $1.35 million funding for the VIPER diagnostic validation program. Dr. Tim Henrich leads research on viral persistence and ImmunoPET-CT imaging.
  • University of PennsylvaniacoreStrategic or Co-development PartnerUniversity of Pennsylvania is part of the Long COVID Research Consortium. Dr. John Wherry's lab studies T cell responses and exhaustion in Long COVID.
  • J. Craig Venter InstitutecoreStrategic or Co-development PartnerJ. Craig Venter Institute is part of the Long COVID Research Consortium. Dr. Marcelo Freire's lab at JCVI studies oral pathogens and chronic disease.
  • Mount Sinai Center for Post-COVID CarecoreStrategic or Co-development PartnerMount Sinai's Center for Post-COVID Care, launched in May 2020 as the first major multidisciplinary Long COVID treatment and research center in the USA, collaborates on clinical trials and research projects.
  • Feinstein Institutes for Medical ResearchsecondaryStrategic or Co-development PartnerDr. Kevin Tracey, president and CEO of Feinstein Institutes, is interviewed by PolyBio and is an expert on vagus nerve signaling and bioelectronic medicine relevant to Long COVID research.
  • Tulane University National Primate Research CentersecondaryStrategic or Co-development PartnerDr. Monica Embers' lab at Tulane studies Borrelia burgdorferi (Lyme disease) and is interviewed by PolyBio for Lyme and tissue research collaboration.
  • Northeastern UniversitysecondaryStrategic or Co-development PartnerDr. Kim Lewis, University Distinguished Professor at Northeastern and Director of the Antimicrobial Discovery Center, collaborates on Lyme disease persister cell research.
  • Arizona State University Banner Neurodegenerative Disease Research CentercoreStrategic or Co-development PartnerDr. Benjamin Readhead's team at ASU is validating a cytomegalovirus-based biomarker for Alzheimer's disease and studying infectious contributions to neurodegenerative diseases.
  • University of Massachusetts Medical SchoolsecondaryStrategic or Co-development PartnerDr. Liisa Selin's lab studies T cell exhaustion and viral activity in ME/CFS, collaborating on understanding immune responses in chronic illness.
  • University of Pennsylvania School of MedicinesecondaryStrategic or Co-development PartnerDr. Sara Cherry's lab uses tissue models and screening technologies to identify antiviral strategies for SARS-CoV-2 persistence research.
  • Commercialization Advisory NetworkcoreOthersA new initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

PolyBio competitors and assessment

Company assessment

Direct peers

  • Patient-Led Research Collaborative: Patient-led research collaborative focused on Long COVID and chronic illness, producing peer-reviewed publications. Highly comparable grassroots, patient-centered research model targeting similar conditions.
  • J. Craig Venter Institute: Genomics and infectious disease research organization that is both a PolyBio consortium partner and a peer in microbiome/metagenomic chronic disease research. Direct overlap on pathogen-driven disease research.
  • Open Medicine Foundation: 501(c)(3) nonprofit research foundation focused on ME/CFS, Long COVID, and related infection-associated chronic diseases. Highly comparable mission, funding model, and disease focus as PolyBio.
  • Solve M.E. Long-standing nonprofit organization dedicated to ME/CFS and Long COVID research, advocacy, and patient support. Overlapping disease focus, philanthropic funding model, and research consortium structure.
  • Cohen Center for Recovery from Complex Chronic Illness (Mount Sinai): Clinical and research center at Mount Sinai focused on Long COVID and complex chronic illness; receives PolyBio funding and conducts clinical trials in the same disease space.

Broad incumbents

  • Howard Hughes Medical Institute: Large biomedical research organization funding investigator-driven science across universities. Comparable model of distributing research funding to top-tier academic labs to drive discovery.
  • Scripps Research Translational Institute: Major biomedical research institute conducting translational research on chronic and infectious diseases. Overlapping scientific scope on pathogen persistence and microbiome-driven disease.
  • NIH RECOVER Initiative: Federal research initiative with >$1B funding dedicated to studying Long COVID. Operates in the same disease area with vastly greater resources; both share the goal of understanding post-viral chronic illness.
  • Chan Zuckerberg Initiative (CZI Biohub): Major philanthropic initiative funding biomedical research, including infectious disease and inflammation. Overlapping mission in advancing disease research via academic partnerships and large-scale funding.

Emerging players

  • Innovative Genomics Institute: Research institute focused on CRISPR and genomic approaches to infectious disease and chronic illness. Comparable emerging research organization with overlap in pathogen-driven disease focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

PolyBio social profiles

Digital presence

PolyBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PolyBio leadership team

Management profile

Number of profiles

Profiles16 records

PolyBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PolyBio M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PolyBio

What does PolyBio do?

PolyBio Research Foundation is a 501(c)(3) nonprofit research foundation that coordinates collaborative research on how viral, bacterial, and parasite infections drive chronic disease and aging. It funds and manages the Long COVID Cure Initiative, the VIPER diagnostic validation program, the Long COVID Research Consortium, multiple clinical trials (including low-dose rapamycin and repurposed HIV antivirals), and the MENSA diagnostic testing platform for Long COVID, ME/CFS, and Chronic Lyme Disease.

Is PolyBio a public or private company?

PolyBio is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was PolyBio founded?

PolyBio was founded in 2021. It employs 1 to 10 people.

Where is PolyBio based?

PolyBio is headquartered in Medford, United States, in the North America region.

How does PolyBio make money?

Two revenue lines are on record. Philanthropic Donations are the primary driver. The others are research Grants and Funding.

Who are PolyBio's main competitors?

Direct peers on record are Patient-Led Research Collaborative, J. Craig Venter Institute, Open Medicine Foundation, Solve M.E. and Cohen Center for Recovery from Complex Chronic Illness (Mount Sinai). Broad incumbents are Howard Hughes Medical Institute, Scripps Research Translational Institute, NIH RECOVER Initiative and Chan Zuckerberg Initiative (CZI Biohub). Innovative Genomics Institute is listed as an emerging player.

Does PolyBio have an API?

No public API is recorded for PolyBio.

What industry is PolyBio in?

PolyBio's product category is Nonprofit Biomedical Research. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEEPolyBio Announces Inaugural Convergence Summit on Pathogen Persistence Across Chronic Disease and Aging ...Middle EastPolyBio announced its inaugural Convergence Summit on pathogen persistence across chronic disease and aging, to be held November 18–20 at the American Academy of Arts and Sciences. The event will bring together researchers, clinicians, industry leaders, and patients to discuss advances in diagnostics and treatments for infection-associated chronic illnesses.PR NewswirePolyBio Announces Inaugural Convergence Summit on Pathogen Persistence Across Chronic Disease and AgingPolyBio Research Foundation announced its inaugural Convergence Summit on pathogen persistence, held November 18–20 at the American Academy of Arts and Sciences in Cambridge, Massachusetts. The three-day event will examine persistent infections in Long COVID, chronic tick-borne illnesses, neurodegenerative diseases, and aging, with sessions on diagnostics, treatments, and clinical trials.PRESSBEESteve and Judy Pagliuca and Governor Maura Healey Accelerate Major Effort to Deliver Treatments for Long COVID ...Middle EastPolyBio Research Foundation raised $15 million from a coalition of donors to advance diagnostics and clinical trials for Long COVID. The effort is being accelerated by Steve and Judy Pagliuca and Governor Maura Healey, with infrastructure expanding into chronic Lyme disease.PR NewswireSteve and Judy Pagliuca and Governor Maura Healey Accelerate Major Effort to Deliver Treatments for Long COVIDPolyBio Research Foundation raised $15 million for its Long COVID Cure Initiative, announced at a September 15 event co-hosted by Steve and Judy Pagliuca and Governor Maura Healey. The initiative will support a clinical trials network and expand to chronic Lyme disease. Over 18 million Americans live with Long COVID.PR NewswireVIPER Diagnostics Program Launches as First Phase of PolyBio Long COVID Cure InitiativePolyBio Research Foundation announced the launch of VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort), the first large-scale program designed to rigorously validate diagnostic tests for SARS-CoV-2 persistence and other biological drivers of Long COVID. An initial $1.35 million has been deployed to the University of California San Francisco to initiate the program, which will conduct head-to-head evaluation of leading diagnostic approaches to determine which tests most accurately detect core disease mechanisms. VIPER is the first phase of the Long COVID Cure Initiative, a four-step program designed to translate biological discovery into real-world treatments for millions of people affected by Long COVID.PR NewswireCOVID-19 Virus Can Persist in the Body More Than a Year after InfectionResearch published in Lancet Infectious Diseases and supported by PolyBio Research Foundation found that SARS-CoV-2 viral proteins persisted in the bloodstream for up to 14 months in approximately 25% of 171 participants tested, using a novel ultra-sensitive blood test developed by Harvard Medical School. The study, conducted by a UCSF/Harvard Medical School team, found hospitalized COVID patients had about twice the likelihood of detectable viral persistence compared to non-hospitalized individuals. The findings strengthen evidence linking viral persistence to Long COVID, with researchers calling for sustained government investment to study potential chronic health consequences in both adults and children.PR NewswireNew LongCOVID research launched by PolyBio's global consortium of scientistsPolyBio Research Foundation announced the second phase of its LongCovid Research Consortium, distributing $15 million to fund research and clinical trials focused on SARS-CoV-2 virus persistence in LongCOVID patients. Over a dozen institutions globally participate in the consortium, including scientists from Harvard, University of Pennsylvania, Mount Sinai, Yale, and UCSF, with new teams added in France, the UK, and Sweden. The funding will support research on virus persistence in gut tissue and launch clinical trials evaluating HIV antivirals as a potential treatment for LongCOVID.YaleNewsYale School of Medicine Receives a $575,000 Grant From PolyBio Research Foundation to Fund Long COVID ResearchThe Yale School of Medicine has received a $575,000 grant from the PolyBio Research Foundation to investigate mechanisms by which SARS-CoV-2 persists in Long COVID patients. The research will analyze tissue and blood samples while testing therapeutics like antivirals and stem-loop RNA using mouse models. This initiative aims to clarify viral persistence and inform future clinical trials for chronic conditions.GenengnewsYale Receives Grant to Fund Long COVID ResearchThe PolyBio Research Foundation awarded a $575,000 grant to the Yale School of Medicine and its Center for Infection & Immunity to fund Long COVID research. The project aims to define mechanisms by which SARS-CoV-2 persists in tissue and blood using patient samples and mouse models to test potential therapeutics.